High-throughput screening strategies for targeted identification of therapeutic compounds in colorectal cancer

Future Oncology

Volumn 8, Issue 3, 2012, Pages 259-272

  Bialkowska, Agnieszka B ^a   Yang, Vincent W ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

chemical probes; colorectal cancer; high throughput screen; molecular pathways; targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CATENIN; CALCIMYCIN; CCT 031374; CCT 036477; CCT 070535; CGP 049090; CYTIDINE DERIVATIVE; FOCAL ADHESION KINASE; KRUPPEL LIKE FACTOR 5; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PKF 115584; PKF 118310; PKF 118744; PKF 222815; PROTEIN P53; TRIPHENYLTETRAZOLIUM; UNCLASSIFIED DRUG; UVOMORULIN; VASCULOTROPIN RECEPTOR; ZTM 000990;

CANCER GROWTH; CARCINOGENESIS; CELL INTERACTION; COLORECTAL CANCER; DRUG IDENTIFICATION; DRUG TARGETING; EXON; GENE DELETION; GENE MUTATION; GENE SILENCING; HETEROZYGOSITY LOSS; HIGH THROUGHPUT SCREENING; HUMAN; NATIONAL HEALTH ORGANIZATION; NONHUMAN; NONSENSE MUTATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; WNT SIGNALING PATHWAY;

BETA CATENIN; COLORECTAL NEOPLASMS; DRUG DESIGN; DRUG DISCOVERY; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MOLECULAR TARGETED THERAPY; WNT SIGNALING PATHWAY;

EID: 84858409792     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.12.19     Document Type: Review

References (59)

1. Macarron R, Banks MN, Bojanic D et al. Impact of high-throughput screening in biomedical research. Nat. Rev. Drug Discov. 10(3), 188-195 (2011)
2. Macarron R, Hertzberg RP. Design and implementation of high throughput screening assays. Mol. Biotechnol. 47(3), 270-285 (2011)
3. Fearon ER. Molecular genetics of colorectal cancer. Annu. Rev. Pathol. 6, 479-507 (2011
4. Bamford S, Dawson E, Forbes S et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br. J. Cancer 91(2), 355-358 (2004
5. Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu. Rev. Cell Dev. Biol. 20, 781-810 (2004
6. Liu C, Li Y, Semenov M et al. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 108(6), 837-847 (2002
7. Mao J, Wang J, Liu B et al. Low-density lipoprotein receptor-related protein-5 binds to axin and regulates the canonical Wnt signaling pathway. Mol. Cell 7(4), 801-809 (2001
8. Schweizer L, Varmus H. Wnt/Wingless signaling through beta-catenin requires the function of both LRP/Arrow and frizzled classes of receptors. BMC Cell Biol. 4, 4 (2003
9. Gregorieff A, Pinto D, Begthel H, Destree O, Kielman M, Clevers H. Expression pattern of Wnt signaling components in the adult intestine. Gastroenterology 129(2), 626-638 (2005
10. Brabletz S, Schmalhofer O, Brabletz T. Gastrointestinal stem cells in development and cancer. J. Pathol. 217(2), 307-317 (2009
11. Haegebarth A, Clevers H. Wnt signaling, lgr5, and stem cells in the intestine and skin. Am. J. Pathol. 174(3), 715-721 (2009
12. Vermeulen L, de Sousa EM, van der Heijden M et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat. Cell Biol. 12(5), 468-476 (2010
13. Barker N, Clevers H. Mining the Wnt pathway for cancer therapeutics. Nat. Rev. Drug Discov. 5(12), 997-1014 (2006
14. Segditsas S, Tomlinson I. Colorectal cancer and genetic alterations in the Wnt pathway. Oncogene 25(57), 7531-7537 (2006
15. Chen B, Dodge ME, Tang W et al. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat. Chem. Biol. 5(2), 100-107 (2009
16. Huang SM, Mishina YM, Liu S et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 461(7264), 614-620 (2009
17. Thorne CA, Hanson AJ, Schneider J et al. Small-molecule inhibition of Wnt signaling through activation of casein kinase 1a. Nat. Chem. Biol. 6(11), 829-836 (2010
18. Ewan K, Pajak B, Stubbs M et al. A useful approach to identify novel small-molecule inhibitors of Wnt-dependent transcription. Cancer Res. 70(14), 5963-5973 (2010
19. Lepourcelet M, Chen YN, France DS et al. Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell 5(1), 91-102 (2004
20. Emami KH, Nguyen C, Ma H et al. A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected]. Proc. Natl Acad. Sci. USA 101(34), 12682-12687 (2004
21. Gonsalves FC, Klein K, Carson BB et al. An RNAi-based chemical genetic screen identifies three small-molecule inhibitors of the Wnt/wingless signaling pathway. Proc. Natl Acad. Sci. USA 108(15), 5954-5963 (2011
22. Baum B, Georgiou M. Dynamics of adherens junctions in epithelial establishment, maintenance, and remodeling. J. Cell Biol. 192(6), 907-917 (2011
23. Dasgupta R, Kaykas A, Moon RT, Perrimon N. Functional genomic analysis of the Wnt-wingless signaling pathway. Science 308(5723), 826-833 (2005
24. Boye K, Maelandsmo GM. S100A4 and metastasis: A small actor playing many roles. Am. J. Pathol. 176(2), 528-535 (2010
25. Stein U, Burock S, Herrmann P et al. Diagnostic and prognostic value of metastasis inducer S100A4 transcripts in plasma of colon, rectal, and gastric cancer patients. J. Mol. Diagn. 13(2), 189-198 (2011
26. Sack U, Stein U. Wnt up your mind - intervention strategies for S100A4-induced metastasis in colon cancer. Gen. Physiol. Biophys. 28(Spec No Focus), F55-F64 (2009
27. Sack U, Walther W, Scudiero D et al. S100A4-induced cell motility and metastasis is restricted by the Wnt/beta-catenin pathway inhibitor calcimycin in colon cancer cells. Mol. Biol. Cell 22(18), 3344-3354 (2011
28. Sack U, Walther W, Scudiero D et al. Novel effect of antihelminthic niclosamide on S100A4-mediated metastatic progression in colon cancer. J. Natl Cancer Inst. 103(13), 1018-1036 (2011
29. Krasinskas AM. EGFR signaling in colorectal carcinoma. Patholog. Res. Int. 2011, 932932 (2011
30. Castellano E, Downward J. RAS interaction with PI3K: More than just another effector pathway. Genes Cancer 2(3), 261-274 (2011
31. Zhang W, Liu HT. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res. 12(1), 9-18 (2002
32. De Roock W, De Vriendt V, Normanno N, Ciardiello F, Tejpar S. KRAS, BRAF, PIK3CA, and PTEN mutations: Implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol. 12(6), 594-603 (2011
33. Torrance CJ, Agrawal V, Vogelstein B, Kinzler KW. Use of isogenic human cancer cells for high-throughput screening and drug discovery. Nature Biotechnol. 19(10), 940-945 (2001
34. Mallon R, Feldberg L, Kim S et al. Identification of 4-anilino-3- quinolinecarbonitrile inhibitors of mitogen-activated protein/extracellular signal-regulated kinase 1 kinase. Mol. Cancer Ther. 3(6), 755-762 (2004
35. McConnell BB, Ghaleb AM, Nandan MO, Yang VW. The diverse functions of Kruppel-like factors 4 and 5 in epithelial biology and pathobiology. Bioessays 29(6), 549-557 (2007
36. McConnell BB, Yang VW. Mammalian Kruppel-like factors in health and diseases. Physiol. Rev. 90(4), 1337-1381 (2010
37. Bialkowska AB, Crisp M, Bannister T et al. Identification of small-molecule inhibitors of the colorectal cancer oncogene Kruppel-like factor 5 expression by ultrahigh-throughputscreening. Mol. Cancer Ther. 10(11), 2043-2051 (2011
38. Samuels Y, Waldman T. Oncogenic mutations of PIK3CA in human cancers. Curr. Top. Microbiol. Immunol. 347, 21-41 (2010
39. Zhang J, Roberts TM, Shivdasani RA. Targeting PI3K signaling as a therapeutic approach for colorectal cancer. Gastroenterology 141(1), 50-61 (2011
40. Vanhaesebroeck B, Alessi DR. The PI3K-PDK1 connection: More than just a road to PKB. Biochem. J. 346(Pt 3), 561-576 (2000
41. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem. 273(22), 13375-13378 (1998
42. Salmena L, Carracedo A, Pandolfi PP. Tenets of PTEN tumor suppression. Cell 133(3), 403-414 (2008
43. Nosho K, Kawasaki T, Ohnishi M et al. PIK3CA mutation in colorectal cancer: Relationship with genetic and epigenetic alterations. Neoplasia 10(6), 534-541 (2008
44. Simi L, Pratesi N, Vignoli M et al. High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. Am. J. Clin. Pathol. 130(2), 247-253 (2008
45. Goel A, Arnold CN, Niedzwiecki D et al. Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Res. 64(9), 3014-3021 (2004
46. Li HF, Keeton A, Vitolo M et al. A high-throughput screen with isogenic PTEN+/+ and PTEN-/- cells identifies CID1340132 as a novel compound that induces apoptosis in PTEN and PIK3CA mutant human cancer cells. J. Biomol. Screen. 16(4), 383-393 (2011
47. He G, Siddik ZH, Huang Z et al. Induction of p21 by p53 following DNA damage inhibits both Cdk4 and Cdk2 activities. Oncogene 24(18), 2929-2943 (2005
48. Suzuki K, Matsubara H. Recent advances in p53 research and cancer treatment. J. Biomed. Biotechnol. 2011, 978312 (2011
49. Hemann MT, Lowe SW. The p53-Bcl-2 connection. Cell Death Differ. 13(8), 1256-1259 (2006
50. Iacopetta B. TP53 mutation in colorectal cancer. Hum. Mutat. 21(3), 271-276 (2003
51. Rivlin N, Brosh R, Oren M, Rotter V. Mutations in the p53 tumor suppressor gene: Important milestones at the various steps of tumorigenesis. Genes Cancer 2(4), 466-474 (2011
52. Wang W, Kim SH, El-Deiry WS. Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts. Proc. Natl Acad. Sci. USA 103(29), 11003-11008 (2006
53. Golubovskaya VM, Finch R, Kweh F et al. p53 regulates FAK expression in human tumor cells. Mol. Carcinogen. 47(5), 373-382 (2008
54. Golubovskaya VM, Cance W. Focal adhesion kinase and p53 signal transduction pathways in cancer. Front. Biosci. 15, 901-912 (2010
55. Golubovskaya VM, Figel S, Ho BT et al. Novel small molecule drugs targeting the main autophosphorylation site (Y397) of focal adhesion kinase are effective colon cancer therapeutics. Presented at: The American Association for Cancer Research Special Conference: Colorectal Cancer: Biology to Therapy. Philadelphia, PA, USA, 27-30 October, 2010.
56. Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal transition: New insights in signaling, development, and disease. J. Cell Biol. 172(7), 973-981 (2006
57. Tsanou E, Peschos D, Batistatou A, Charalabopoulos A, Charalabopoulos K. The E-cadherin adhesion molecule and colorectal cancer. A global literature approach. Anticancer Res. 28(6A), 3815-3826 (2008
58. Wheeler JM, Kim HC, Efstathiou JA, Ilyas M, Mortensen NJ, Bodmer WF. Hypermethylation of the promoter region of the E-cadherin gene (CDH1) in sporadic and ulcerative colitis associated colorectal cancer. Gut 48(3), 367-371 (2001
59. Stoops SL, Pearson AS, Weaver C et al. Identification and optimization of small molecules that restore E-cadherin expression and reduce invasion in colorectal carcinoma cells. ACS Chem. Biol. 6(5), 452-465 (2011).